Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of CMS121 and Unifiram — mechanism, side effects, legal status, and pricing.
CMS121 is a non-peptide small-molecule quinoline, a synthetic analog of the natural flavonoid fisetin, developed to inhibit fatty acid synthase (FASN) and reduce lipid peroxidation in neuronal cells. It has completed a Phase 1 safety and pharmacokinetics trial in healthy volunteers (NCT05318040) but has no approved medical use and no published human efficacy data in Alzheimer's disease or any other condition. The compound is sold by research-chemical suppliers for laboratory use only; some direct-to-consumer vendors incorrectly market it as a "peptide" supplement despite its small-molecule structure.
Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.
CMS121
Unifiram
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
CMS121
Unifiram
COA corpus from Disclosed Labs — independently tested batches only.
CMS121
3
COAs
99.1%
Avg purity
2
Labs
Unifiram
1
COAs
99.4%
Avg purity
1
Labs
In APPswe/PS1dE9 double-transgenic mice (a model of Alzheimer's disease), dietary CMS121 (~34 mg/kg/day for 3 months starting at 9 months of age) normalized elevated hippocampal 4-HNE lipid-peroxidation adducts to wild-type levels, reduced 15-LOX2 and GFAP expression, and reversed cognitive deficits in Morris water maze testing to performance indistinguishable from wild-type mice. In vitro, CMS121 reduced iNOS, COX2, and TNF-α induction and blunted lipid-peroxidation increases in LPS-activated microglial cell cultures. A completed Phase 1 trial in approximately 100 healthy volunteers (NCT05318040) tested single oral doses up to 1800 mg and repeat doses up to 900 mg/day in young adults (600 mg/day in elderly subjects) for 7 days, reporting generally well-tolerated safety profiles with the majority of adverse events classified as mild; no serious adverse events were reported. Elderly subjects showed higher systemic exposure and longer terminal half-life than young adults, and fed-state exposure was approximately 50% higher than fasted with delayed absorption. No human efficacy data exist in Alzheimer's disease patients or any patient population.
Key references
No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.
CMS121 and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs